Mikhail Blagosklonny MD, PhD, is a renowned cancer and aging scientist. Currently, he is an oncology professor at Roswell Park Cancer Institute in New York. Mikhail enrolled in the First Pavlov State Medical University of St. Petersburg where he graduated with his M.D in internal medicine and a PhD in experimental medicine and cardiology. In 2002, he worked for New York Medical College Valhalla, NY as the associate professor of medicine. Later, Mikhail joined Ordway Research Institute where he worked as a senior scientist until 2009 when he joined Roswell Park Cancer Institute.
Mikhail’s research covers a wide range of topics, including cellular and molecular biology, and clinical investigations. He has a particular interest in researching about oncogenes and tumor suppressors, apoptosis, mitosis, cell cycle and signal transduction. He also analyses anticancer therapeutics focusing more on translation of basic science into anticancer strategies like exploiting cancer cell cycling and drug resistance’s role for protecting normal cells. has extended his approach to aging and cancer, and other age-related diseases by formulating a hypothesis to study the possible role of TOR Signaling. This study proposed the use of a popular cancer drug called rapamycin as a possible drug for life extension. Mikhail Blagosklonny is regarded as one of the most passionate advocates for rapamycin drug.
He is the author of hyper-function theory of aging as well the brain behind chemotherapeutic engineering and cell cyclotherapy, which are anti-cancer approaches. Dr. Blagosklonny has published over 300 articles, book chapters, and reviews. He is the editor-in-chief of Oncotarget, Aging and Cell Cycle journals. Oncotarget is a multidisciplinary peer-reviewed open access journal that publishes papers on all aspects of oncology on a weekly basis. Aging is a peer-reviewed open access medical journal, which is published monthly by Impact Journal. Cell cycle is a peer-reviewed scientific journal that covers topics on cell biology. It is released twice a week. Mikhail is also an associate editor of Cancer Biology & Therapy. He sits on the editorial board of Cell Death & Differentiate. Previously, he served as an associate editor for Cancer Research, International Journal of Cancer, Cell Death and Differentiation, PLOS ONE and American Journal of Cancer. View Mikhail’s profile in LinkedIn.